Microarray  ||| S:0 E:11 ||| JJ
studies  ||| S:11 E:19 ||| NNS
in  ||| S:19 E:22 ||| IN
pulmonary  ||| S:22 E:32 ||| FW
arterial  ||| S:32 E:41 ||| FW
hypertension  ||| S:41 E:54 ||| FW
Microarray  ||| S:54 E:65 ||| FW
studies  ||| S:65 E:73 ||| NNS
have  ||| S:73 E:78 ||| VBP
been  ||| S:78 E:83 ||| VBN
performed  ||| S:83 E:93 ||| VBN
on  ||| S:93 E:96 ||| IN
lung  ||| S:96 E:101 ||| NN
tissue ||| S:101 E:107 ||| NN
,  ||| S:107 E:109 ||| ,
freshly  ||| S:109 E:117 ||| RB
isolated  ||| S:117 E:126 ||| VBN
circulating  ||| S:126 E:138 ||| VBG
cells  ||| S:138 E:144 ||| NNS
and  ||| S:144 E:148 ||| CC
cells  ||| S:148 E:154 ||| NNS
cultured  ||| S:154 E:163 ||| VBN
from  ||| S:163 E:168 ||| IN
patients  ||| S:168 E:177 ||| NNS
with  ||| S:177 E:182 ||| IN
idiopathic ||| S:182 E:192 ||| NN
,  ||| S:192 E:194 ||| ,
hereditary  ||| S:194 E:205 ||| NN
and  ||| S:205 E:209 ||| CC
secondary  ||| S:209 E:219 ||| JJ
forms  ||| S:219 E:225 ||| NNS
of  ||| S:225 E:228 ||| IN
pulmonary  ||| S:228 E:238 ||| FW
arterial  ||| S:238 E:247 ||| FW
hypertension  ||| S:247 E:260 ||| FW
( ||| S:260 E:261 ||| -LRB-
PAH ||| S:261 E:264 ||| NNP
) ||| S:264 E:265 ||| -RRB-
.  ||| S:265 E:267 ||| .
These  ||| S:267 E:273 ||| DT
studies  ||| S:273 E:281 ||| NNS
have  ||| S:281 E:286 ||| VBP
provided  ||| S:286 E:295 ||| VBN
a  ||| S:295 E:297 ||| DT
wealth  ||| S:297 E:304 ||| NN
of  ||| S:304 E:307 ||| IN
information  ||| S:307 E:319 ||| NN
on  ||| S:319 E:322 ||| IN
the  ||| S:322 E:326 ||| DT
characteristics  ||| S:326 E:342 ||| NN
of  ||| S:342 E:345 ||| IN
end-stage  ||| S:345 E:355 ||| JJ
disease ||| S:355 E:362 ||| NN
,  ||| S:362 E:364 ||| ,
but  ||| S:364 E:368 ||| CC
information  ||| S:368 E:380 ||| NN
about  ||| S:380 E:386 ||| IN
the  ||| S:386 E:390 ||| DT
origin  ||| S:390 E:397 ||| NN
of  ||| S:397 E:400 ||| IN
disease  ||| S:400 E:408 ||| NN
is  ||| S:408 E:411 ||| VBZ
only  ||| S:411 E:416 ||| RB
clear  ||| S:416 E:422 ||| JJ
in  ||| S:422 E:425 ||| IN
hindsight ||| S:425 E:434 ||| NN
.  ||| S:434 E:436 ||| .
The  ||| S:436 E:440 ||| DT
central  ||| S:440 E:448 ||| JJ
conclusions  ||| S:448 E:460 ||| NNS
that  ||| S:460 E:465 ||| WDT
can  ||| S:465 E:469 ||| MD
be  ||| S:469 E:472 ||| VB
drawn  ||| S:472 E:478 ||| VBN
from  ||| S:478 E:483 ||| IN
these  ||| S:483 E:489 ||| DT
studies  ||| S:489 E:497 ||| NNS
are  ||| S:497 E:501 ||| VBP
that  ||| S:501 E:506 ||| IN
end-stage  ||| S:506 E:516 ||| JJ
disease  ||| S:516 E:524 ||| NN
includes  ||| S:524 E:533 ||| VBZ
a  ||| S:533 E:535 ||| DT
massive  ||| S:535 E:543 ||| JJ
but  ||| S:543 E:547 ||| CC
currently  ||| S:547 E:557 ||| RB
poorly  ||| S:557 E:564 ||| RB
defined  ||| S:564 E:572 ||| VBN
inflammatory  ||| S:572 E:585 ||| JJ
response ||| S:585 E:593 ||| NN
,  ||| S:593 E:595 ||| ,
induction  ||| S:595 E:605 ||| VBG
of  ||| S:605 E:608 ||| IN
angiogenesis  ||| S:608 E:621 ||| JJ
genes  ||| S:621 E:627 ||| NNS
for  ||| S:627 E:631 ||| IN
an  ||| S:631 E:634 ||| DT
as  ||| S:634 E:637 ||| RB
yet  ||| S:637 E:641 ||| RB
remaining  ||| S:641 E:651 ||| VBG
unknown  ||| S:651 E:659 ||| JJ
purpose ||| S:659 E:666 ||| NN
,  ||| S:666 E:668 ||| ,
suppression  ||| S:668 E:680 ||| NN
of  ||| S:680 E:683 ||| IN
the  ||| S:683 E:687 ||| DT
BMP  ||| S:687 E:691 ||| NN
pathway  ||| S:691 E:699 ||| VBZ
even  ||| S:699 E:704 ||| RB
in  ||| S:704 E:707 ||| IN
idiopathic  ||| S:707 E:718 ||| NN
and  ||| S:718 E:722 ||| CC
secondary  ||| S:722 E:732 ||| JJ
cases ||| S:732 E:737 ||| NNS
,  ||| S:737 E:739 ||| ,
and  ||| S:739 E:743 ||| CC
a  ||| S:743 E:745 ||| DT
host  ||| S:745 E:750 ||| NN
of  ||| S:750 E:753 ||| IN
more  ||| S:753 E:758 ||| RBR
subtle  ||| S:758 E:765 ||| JJ
changes ||| S:765 E:772 ||| NNS
,  ||| S:772 E:774 ||| ,
including  ||| S:774 E:784 ||| VBG
mitochondrial  ||| S:784 E:798 ||| NNS
and  ||| S:798 E:802 ||| CC
actin  ||| S:802 E:808 ||| JJ
organisation  ||| S:808 E:821 ||| JJ
changes ||| S:821 E:828 ||| NNS
.  ||| S:828 E:830 ||| .
Moreover ||| S:830 E:838 ||| RB
,  ||| S:838 E:840 ||| ,
the  ||| S:840 E:844 ||| DT
same  ||| S:844 E:849 ||| JJ
physiologic  ||| S:849 E:861 ||| JJ
endpoints  ||| S:861 E:871 ||| NN
can  ||| S:871 E:875 ||| MD
be  ||| S:875 E:878 ||| VB
achieved  ||| S:878 E:887 ||| VBN
through  ||| S:887 E:895 ||| IN
use  ||| S:895 E:899 ||| NN
of  ||| S:899 E:902 ||| IN
any  ||| S:902 E:906 ||| DT
of  ||| S:906 E:909 ||| IN
multiple  ||| S:909 E:918 ||| JJ
genes ||| S:918 E:923 ||| NNS
,  ||| S:923 E:925 ||| ,
and  ||| S:925 E:929 ||| CC
so  ||| S:929 E:932 ||| RB
specific  ||| S:932 E:941 ||| JJ
genes  ||| S:941 E:947 ||| NNS
are  ||| S:947 E:951 ||| VBP
usually  ||| S:951 E:959 ||| RB
less  ||| S:959 E:964 ||| RBR
important  ||| S:964 E:974 ||| JJ
than  ||| S:974 E:979 ||| IN
the  ||| S:979 E:983 ||| DT
pathways  ||| S:983 E:992 ||| NN
they  ||| S:992 E:997 ||| PRP
lie  ||| S:997 E:1001 ||| VBP
in ||| S:1001 E:1003 ||| IN
;  ||| S:1003 E:1005 ||| :
the  ||| S:1005 E:1009 ||| DT
exception  ||| S:1009 E:1019 ||| NN
to  ||| S:1019 E:1022 ||| TO
this  ||| S:1022 E:1027 ||| DT
rule  ||| S:1027 E:1032 ||| NN
must  ||| S:1032 E:1037 ||| MD
lie  ||| S:1037 E:1041 ||| VB
in  ||| S:1041 E:1044 ||| IN
as  ||| S:1044 E:1047 ||| RB
yet  ||| S:1047 E:1051 ||| RB
undefined  ||| S:1051 E:1061 ||| JJ
critical  ||| S:1061 E:1070 ||| JJ
nodes ||| S:1070 E:1075 ||| NN
.  ||| S:1075 E:1077 ||| .
Finally ||| S:1077 E:1084 ||| RB
,  ||| S:1084 E:1086 ||| ,
the  ||| S:1086 E:1090 ||| DT
lack  ||| S:1090 E:1095 ||| NN
of  ||| S:1095 E:1098 ||| IN
consistency  ||| S:1098 E:1110 ||| NN
in  ||| S:1110 E:1113 ||| IN
methodologies  ||| S:1113 E:1127 ||| NNS
of  ||| S:1127 E:1130 ||| IN
analysis  ||| S:1130 E:1139 ||| NN
makes  ||| S:1139 E:1145 ||| VBZ
cross-experiment  ||| S:1145 E:1162 ||| JJ
comparisons  ||| S:1162 E:1174 ||| NNS
difficult ||| S:1174 E:1183 ||| JJ
,  ||| S:1183 E:1185 ||| ,
and  ||| S:1185 E:1189 ||| CC
likely  ||| S:1189 E:1196 ||| JJ
means  ||| S:1196 E:1202 ||| NNS
that  ||| S:1202 E:1207 ||| IN
there  ||| S:1207 E:1213 ||| EX
is  ||| S:1213 E:1216 ||| VBZ
data  ||| S:1216 E:1221 ||| NNS
collected  ||| S:1221 E:1231 ||| VBN
in  ||| S:1231 E:1234 ||| IN
these  ||| S:1234 E:1240 ||| DT
studies  ||| S:1240 E:1248 ||| NNS
that  ||| S:1248 E:1253 ||| WDT
await  ||| S:1253 E:1259 ||| VBP
interpretation ||| S:1259 E:1273 ||| NN
.  ||| S:1273 E:1275 ||| .
